[1] 国家卫生健康委员会. 儿童肺炎支原体肺炎诊疗指南(2023年版)[J]. 传染病信息, 2023, 36(4): 291-297. doi:  10.3969/j.issn.1007-8134.2023.04.002
[2] 范志诚, 戴红臣. 阿奇霉素和红霉素用于肺炎支原体感染患儿的临床分析[J/OL]. 中华肺部疾病杂志(电子版), 2023, 16(3): 385-387.
[3] 林莉, 狄天伟, 杨爱娟, 等. 儿童肺炎支原体感染流行病学特征分析[J]. 中国病原生物学杂志, 2023, 18(11): 1333-1336.
[4] 刘雪. 大环内酯类药物治疗小儿支原体感染的药学分析[J]. 名医, 2023(10): 156-158. doi:  10.3969/j.issn.1674-9561.mingy202310054
[5] EDWARDS B J, BUNTA A D, LANE J, et al. Bisphosphonates and nonhealing femoral fractures: analysis of the FDA adverse event reporting system(FAERS)and international safety efforts: a systematic review from the research on adverse drug events and reports(RADAR)project[J]. J Bone Joint Surg Am, 2013, 95(4): 297-307. doi:  10.2106/JBJS.K.01181
[6] ALATAWI Y M, HANSEN R A. Empirical estimation of under-reporting in the U. S. food and drug administration adverse event reporting system (FAERS)[J]. Expert Opin Drug Saf, 2017, 16(7): 761-767. doi:  10.1080/14740338.2017.1323867
[7] BROWN E G. Using MedDRA: implications for risk management[J]. Drug Saf, 2004, 27(8): 591-602. doi:  10.2165/00002018-200427080-00010
[8] ROTHMAN K J, LANES S, SACKS S T. The reporting odds ratio and its advantages over the proportional reporting ratio[J]. Pharmacoepidemiol Drug Saf, 2004, 13(8): 519-523. doi:  10.1002/pds.1001
[9] EVANS S J, WALLER P C, DAVIS S. Use of proportional reporting ratios(PRRs)for signal generation from spontaneous adverse drug reaction reports[J]. Pharmacoepidemiol Drug Saf, 2001, 10(6): 483-486. doi:  10.1002/pds.677
[10] BATE A, LINDQUIST M, EDWARDS I R, et al. A Bayesian neural network method for adverse drug reaction signal generation[J]. Eur J Clin Pharmacol, 1998, 54(4): 315-321. doi:  10.1007/s002280050466
[11] DUMOUCHEL W. Bayesian data mining in large frequency tables, with an application to the FDA spontaneous reporting system[J]. Am Stat, 1999, 53(3): 177-190. doi:  10.1080/00031305.1999.10474456
[12] 马攀, 龚莉, 张妮, 等. 基于FDA不良事件数据库对洛匹那韦/利托那韦安全信号的检测与分析[J]. 中国现代应用药学, 2020, 37(4): 406-413.
[13] 鲁晴, 王伟明. 抗Hp感染中克拉霉素致药物性口炎1例[J]. 中国民族民间医药, 2016, 25(5): 40. doi:  10.3969/j.issn.1007-8517.2016.5.zgmzmjyyzz201605019
[14] WAITES K B, TALKINGTON D F. Mycoplasma pneumoniae and its role as a human pathogen[J]. Clin Microbiol Rev, 2004, 17(4): 697-728.
[15] USONIS V, IVASKEVICIUS R, DIEZ-DOMINGO J, et al. Comparison between diagnosis and treatment of community-acquired pneumonia in children in various medical centres across Europe with the United States, United Kingdom and the World Health Organization guidelines[J]. Pneumonia (Nathan), 2016, 8: 5. doi:  10.1186/s41479-016-0005-y
[16] 王家满, 韩琼. 克拉霉素、阿奇霉素药物不良反应的分析[J]. 中国现代药物应用, 2015, 9(1): 92-93.
[17] 黄开华. 万载县株潭中心卫生院门诊患者阿奇霉素与克拉霉素临床用药情况分析[J]. 临床合理用药杂志, 2019, 12(12): 122-123.
[18] ALVAREZ-ELCORO S, ENZLER M J. The macrolides: erythromycin, clarithromycin, and azithromycin[J]. Mayo Clin Proc, 1999, 74(6): 613-634. doi:  10.4065/74.6.613
[19] 辉瑞制药科技有限公司. 阿奇霉素片说明书[EB/OL].(2022-05-31). [2024-02-22]. https://labeling.pfizer.com/ShowLabeling.aspx?id=14475.
[20] SHAEER K M, CHAHINE E B, VARGHESE GUPTA S, et al. Macrolide allergic reactions[J]. Pharmacy, 2019, 7(3): 135.
[21] BENAHMED S, SCARAMUZZA C, MESSAAD D, et al. The accuracy of the diagnosis of suspected macrolide antibiotic hypersensitivity: results of a single-blinded trial[J]. Allergy, 2004, 59(10): 1130-1133. doi:  10.1111/j.1398-9995.2004.00638.x
[22] MORI F, PECORARI L, PANTANO S, et al. Azithromycin anaphylaxis in children[J]. Int J Immunopathol Pharmacol, 2014, 27(1): 121-126. doi:  10.1177/039463201402700116
[23] ARAÚJO L, DEMOLY P. Macrolides allergy[J]. Curr Pharm Des, 2008, 14(27): 2840-2862. doi:  10.2174/138161208786369812
[24] BARNI S, BUTTI D, MORI F, et al. Azithromycin is more allergenic than clarithromycin in children with suspected hypersensitivity reaction to macrolides[J]. J Investig Allergol Clin Immunol, 2015, 25(2): 128-132.
[25] 陈煜. 阿奇霉素和克拉霉素治疗患者药物不良反应的临床分析[J]. 北方药学, 2020, 17(7): 186-187. doi:  10.3969/j.issn.1672-8351.2020.07.138
[26] 上海雅培制药有限公司. 克拉霉素片说明书[EB/OL]. (2017-10-19). [2024-02-22]. https://labeling.pfizer.com/ShowLabeling.aspxid=14475.
[27] NTEMI P V, WALKER R B, KHAMANGA S M. Design, evaluation and optimization of taste masked clarithromycin powder[J]. Pharmazie, 2019, 74(12): 721-727.
[28] YOUNG M J, CAPLAN R A, CONNOLLY I, et al. Closed-eye visual hallucinations associated with clarithromycin[J]. J Neuropsychiatry Clin Neurosci, 2021, 33(3): 230-232. doi:  10.1176/appi.neuropsych.20100253
[29] BANDETTINI DI POGGIO M, ANFOSSO S, AUDENINO D, et al. Clarithromycin-induced neurotoxicity in adults[J]. J Clin Neurosci, 2011, 18(3): 313-318. doi:  10.1016/j.jocn.2010.08.014
[30] YASUI N, OTANI K, KANEKO S, et al. Carbamazepine toxicity induced by clarithromycin coadministration in psychiatric patients[J]. Int Clin Psychopharmacol, 1997, 12(4): 225-229. doi:  10.1097/00004850-199707000-00007
[31] GÉLISSE P, HILLAIRE-BUYS D, HALAILI E, et al. Carbamazepine and clarithromycin: a clinically relevant drug interaction[J]. Rev Neurol, 2007, 163(11): 1096-1099. doi:  10.1016/S0035-3787(07)74183-8
[32] POLLAK P T, SKETRIS I S, MACKENZIE S L, et al. Delirium probably induced by clarithromycin in a patient receiving fluoxetine[J]. Ann Pharmacother, 1995, 29(5): 486-488. doi:  10.1177/106002809502900506
[33] JABER B L, LOBON L F, MADIAS N E. The serotonin syndrome complicating co-prescription of paroxetine and clarithromycin[J]. Am J Med, 2006, 119(4): e3. doi:  10.1016/j.amjmed.2005.05.022
[34] PRIME K, FRENCH P. Neuropsychiatric reaction induced by clarithromycin in a patient on highly active antiretroviral therapy(HAART)[J]. Sex Transm Infect, 2001, 77(4): 297-298. doi:  10.1136/sti.77.4.297
[35] SAKAEDA T, TAMON A, KADOYAMA K, et al. Data mining of the public version of the FDA adverse event reporting system[J]. Int J Med Sci, 2013, 10(7): 796-803. doi:  10.7150/ijms.6048